Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Canagliflozin in peritoneal dialysis patients with type 2 diabetes
jRCT1011210022Active, not recruiting
- Start
- Aug 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Randomised, open-label trial of canagliflozin in type 2 diabetes mellitus (T2DM) and chronic kidney disease (CKD) (2 arms). Primary endpoint: B-type natriuretic peptide. Started Aug 2021; status: active, not recruiting.
02
Drugs
canagliflozin
03
Conditions
type 2 diabetes mellitus (T2DM)chronic kidney disease (CKD)
Beyond the preview
Go deeper on jRCT1011210022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT1011210022.